Drug Combination Details
| General Information of the Combination (ID: C45701) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Cytarabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Bone marrow samples from newly diagnosed AML patients | Acute myeloid leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin down regulates MDR genes. Curcumin can be used as MDR modulator as well as chemosensitizer in combination with cytarabine to reduce the cytotoxicity profile as IC50 value decreases when treated in combination. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergism of Curcumin and Cytarabine in the Down Regulation of Multi-Drug Resistance Genes in Acute Myeloid Leukemia. Anticancer Agents Med Chem. 2016;16(1):128-35. | |||
